# Experimental Gene Therapy Reduces Epileptic Seizures by 90 Percent A novel chemogenetic approach offers hope for patients with drug-resistant epilepsy. - **Source:** [The Independent Science](https://www.independent.co.uk/news/science/rss) - **Published:** 2026-11-06 - **Topic:** [health](https://brifing.si/c/health) - **Original article:** - **On Brifing:** https://brifing.si/s/8ebd832a-16e6-482d-abbb-4ecb0e8edeee ## Breakthrough in Seizure Control An experimental gene therapy has demonstrated a remarkable 90 percent reduction in monthly seizures for patients with drug-resistant epilepsy. Published in The New England Journal of Medicine, this clinical trial offers a potential alternative for individuals who do not respond to standard anti-seizure medications, which currently fail one in three patients. ## Targeting Neural Activity The treatment utilizes an engineered virus to deliver a specific gene directly into the hippocampus. This gene modifies excitatory neurons, allowing them to bind with clozapine. By administering this medication, clinicians can effectively dampen the electrical firing rate of overactive brain cells that trigger convulsions, providing a highly localized therapeutic intervention. ## Significant Clinical Results In the study involving three adult participants, monthly seizure frequency dropped drastically within two months. Two patients saw their seizures fall from 4.5 to 0.5 per month, while the third participant achieved complete seizure freedom. These results highlight the potential of chemogenetics to manage severe neurological conditions with high precision. ## Reversible Therapeutic Mechanism Unlike traditional gene therapies that are permanent and irreversible, this dual approach allows for dose adjustment. By varying the amount of clozapine administered, doctors can modulate the strength of the therapy. This flexibility provides a crucial safety mechanism, as demonstrated when one patient's seizures returned after stopping the medication and ceased upon resumption. ## Preserving Brain Tissue Current standard treatments for drug-resistant epilepsy often require invasive procedures, such as surgically removing damaged brain tissue or using lasers to destroy it. This new technique offers a less destructive alternative by preserving the patient's brain tissue while still utilizing surgical precision to deliver the gene therapy directly to the source. ## Expert Perspectives and Cautions Independent neurologists have praised the dramatic efficacy and minimal side effects observed in the trial. However, experts emphasize that the sample size remains extremely small. There are also concerns regarding the long-term use of clozapine, which can be associated with adverse cardiovascular outcomes and other complications at higher dosage levels. ## Future Research Directions Researchers are now focused on long-term monitoring of the three initial participants to assess the durability of the treatment. Simultaneously, plans are underway to organize larger clinical trials. These future studies will be essential to determine if this technique can be safely scaled to help a broader population of epilepsy patients. ## Addressing Unmet Medical Needs With approximately 600,000 people in the UK living with epilepsy, the burden of drug-resistant forms is significant. Uncontrolled seizures lead to severe injuries, cognitive decline, and increased mortality risks. This innovative gene therapy represents a major step toward addressing these critical health challenges through advanced, targeted, and adjustable medical interventions. ## Sources covering this story - https://www.independent.co.uk/news/science/experimental-gene-therapy-brain-reduces-epileptic-seizures-science-b3080366.html — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._